Binimetinib Synthesis and Related Patents
Binimetinib, also known as MEK162, is a potent and selective inhibitor of MEK1 and MEK2 enzymes [1]. Its synthesis is described in patent application WO2003077914A1, which details a process for preparing substituted pyrazoles [2].
How is Binimetinib Synthesized?
Patent WO2003077914A1 outlines a method for producing binimetinib, involving the preparation of specific substituted pyrazoles. While the exact step-by-step synthesis is proprietary, the patent focuses on intermediates and final compound structures related to MEK inhibitors [2].
What are the Key Patents for Binimetinib?
The primary patent document concerning the synthesis of binimetinib is WO2003077914A1 [2]. Other patents may cover formulations, methods of treatment, and manufacturing processes. Information on patent expiry and related intellectual property for binimetinib can be found on DrugPatentWatch.com [3].
When Does Binimetinib Patent Exclusivity Expire?
Patent expiry dates for drugs like binimetinib determine when generic versions can be introduced. Information regarding the specific patent status and estimated expiry dates for binimetinib is available through patent tracking services [3].
What is Binimetinib Used For?
Binimetinib is approved for the treatment of certain types of cancer, often in combination with other drugs. It targets the MEK pathway, which is involved in cell growth and proliferation [1].
How does Binimetinib work?
Binimetinib functions by inhibiting MEK1 and MEK2, which are critical components of the RAS/RAF/MEK/ERK signaling pathway [1]. This pathway is frequently dysregulated in various cancers, leading to uncontrolled cell division. By blocking MEK, binimetinib can help to slow or stop cancer cell growth.
Are there Generic Alternatives to Binimetinib?
The availability of generic alternatives depends on the expiry of patents protecting binimetinib. Once patents expire, other companies may be able to produce and market generic versions of the drug [3].
Who Developed Binimetinib?
Binimetinib was developed by Array BioPharma, which was later acquired by Pfizer [4].
Sources:
[1] https://www.cancer.gov/about-cancer/treatment/drugs/binimetinib
[2] https://patents.google.com/patent/WO2003077914A1/en
[3] https://drugpatentwatch.com/
[4] https://www.arraybiopharma.com/news-media/press-releases/array-biopharma-announces-completion-of-acquisition-by-pfizer/